Commercialization of a novel treatment for myopia – generation of pharmacokinetic data for Phase II clinical trials

Based on successful completion of pre-market development, our novel ophthalmic compound is ready for clinical testing (Phase II) in a patient population. This is the final clinical hurdle before movement to market. However, to undertake such testing, we are required to generate pharmacokinetic data to obtain pharmaceutical registration and approval by the relevant regulatory bodies (e.g. TGA). We are therefore applying for DTF funding to undertake this work and, in doing so, establish the facilities at UC to support other such projects during drug development and commercialisation.